Search

Your search keyword '"David Lavi"' showing total 31 results

Search Constraints

Start Over You searched for: Author "David Lavi" Remove constraint Author: "David Lavi"
31 results on '"David Lavi"'

Search Results

1. Remote immune processes revealed by immune-derived circulating cell-free DNA

2. Impairments of interpersonal synchrony evident in attention deficit hyperactivity disorder (ADHD)

3. Changing Preference of One- Vs. Two-Stage Implant Placement in Partially Edentulous Individuals: An 18-Year Retrospective Study

4. Influence of Vinyl Polysiloxane Impression Techniques on Marginal Fit of Metal Frameworks for Fixed Partial Dentures

5. Group G Streptococcal Bacteremia in Jerusalem

6. Targeted inhibition of the IL5 axis for immune checkpoint inhibitors eosinophilic-induced adverse events

7. Author response: Remote immune processes revealed by immune-derived circulating cell-free DNA

8. Influence of Vinyl Polysiloxane Impression Techniques on Marginal Fit of Metal Frameworks for Fixed Partial Dentures

9. Impairments of interpersonal synchrony evident in attention deficit hyperactivity disorder (ADHD)

10. Changing Preference of One- Vs. Two-Stage Implant Placement in Partially Edentulous Individuals: An 18-Year Retrospective Study

11. Bone Microstrain Values of 1-Piece and 2-Piece Implants Subjected to Mechanical Loading

12. S213: BMS-986158, A POTENT BET INHIBITOR, AS MONOTHERAPY AND IN COMBINATION WITH RUXOLITINIB OR FEDRATINIB IN INTERMEDIATE- OR HIGH-RISK MYELOFIBROSIS (MF): RESULTS FROM A PHASE 1/2 STUDY

13. P1068: UPDATED RESULTS FROM AN OPEN-LABEL PHASE 1/2 STUDY OF FAVEZELIMAB IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA AFTER ANTI–PD-1 TREATMENT

14. P1065: UPDATED RESULTS FROM AN OPEN-LABEL PHASE 1/2 STUDY OF FAVEZELIMAB IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH ANTI–PD-1–NAIVE RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA

16. P1144: PHASE 2 WAVELINE-004 STUDY: ZILOVERTAMAB VEDOTIN (MK-2140) IN RELAPSED/REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)

17. Clinical outcomes of patients with myelofibrosis after immediate transition to momelotinib from ruxolitinib

18. Retrospective Clinical Evaluation of Tapered Implants

20. Cardiovascular and bone health of former elite infantry soldiers at middle life

21. Group G Streptococcal Bacteremia in Jerusalem

22. Implementation of an organizational infrastructure paediatric plan adapted to bronchiolitis epidemics

23. Generalized Amelogenesis Imperfecta

24. P061: Safety and Dose-Expansion Study of Combination Favezelimab (anti–LAG-3) Plus Pembrolizumab in Anti–PD-1–Naive Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

25. T058: Safety and Dose-Expansion Study of Combination Favezelimab (anti–LAG-3) Plus Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma Refractory to Anti–PD-1 Treatment

26. Anti-CK7/CK20 Immunohistochemistry Did Not Associate with the Metastatic Site in TTF-1-Negative Lung Cancer

27. Results from HARMONY: an open-label, multicenter, 2-arm, phase 1b, dose-finding study assessing the safety and efficacy of the oral combination of ruxolitinib and buparlisib in patients with myelofibrosis

28. Immune Escape Is an Early Event in Pre-Invasive Lesions of Lung Squamous Cell Carcinoma

29. #informetwitter: análisis cualitativo del usuario avanzado de la red social

30. Temperature Field Progression in Annular Tube Around Heated Rod in Respect to the Mass Flow of Coolant

Catalog

Books, media, physical & digital resources